Menu

How Bulgy Bears Keep Diabetes at Bay

A genetic switch in hibernating bears keeps the animals from becoming insulin-resistant. 

Aug 8, 2014
Jyoti Madhusoodanan

FLICKR, DANUpdate (September 2, 2015): This study has been retracted.

Bears pack on the pounds—up to twice their weight—before hibernating. Being obese and sedentary can lead to insulin resistance and, eventually, type 2 diabetes in humans and other species, but grizzly bears dodge the disease. A study published this week (August 5) in Cell Metabolism showed the bears’ insulin sensitivity is reversed during hibernation.

Lynne Nelson of Washington State University in Pullman and her colleagues studied weight fluctuations in six captive grizzly bears over the course of a year to understand how the animals adapted. They discovered that, unlike humans, the bears remained highly sensitive to insulin even at their heaviest: a tiny dose that a person might take proved nearly lethal to the 700-pound grizzlies.  

“The results were so different from what we see in humans and rodents that we were all very skeptical at first,” coauthor Kevin Corbit of the biotechnology firm Amgen told NPR. “This was a complete surprise.”

Molecular studies revealed that this insulin sensitivity was controlled by a protein called PTEN. In the fall, PTEN signaling was switched “off” in bear fat cells, which kept the animals responsive to insulin, allowing them to bulk up. Well into the hibernation process, the bears became insulin-resistant. This process was reversed in the springtime, when the animals emerged from hibernation with normal insulin sensitivity.

Further studies may help reveal molecular switches relevant to human diabetes, the authors suggested. The results are “provocative and interesting,” biologist Sandy Martin of the University of Colorado, Denver, told Science News. “They found a natural solution to a problem that we haven’t been able to solve.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!